DermTech’s cancer test has 99% accuracy in ruling out melanoma
Source: Clinical Trials Arena, January 2024
The California-based DermTech has announced positive results from its Trust 2 study,tevaluating its system for ruling out melanoma showing a negative predictive value (NPV) of 99.7%.
DermTech reported positive topline results from the Trust 2 trial, which examined the gene expression assay component of the DermTech Melanoma Test (DMT).
The study results demonstrated an NPV of 99.7% for the foundational gene expression assay component of the company’s melanoma test. The study results also included a sensitivity of 95.8%, a specificity of 69.4% and a positive predictive value (PPV) of 13.4%.